Drug Trial Radar · NCT07909655
A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jan 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a 58 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of HB0056, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF.
Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
Interventions
HB0056Drug
subjects be given HB0056 high dose
HB0056Drug
subjects be given HB0056 low dose
PlaceboDrug
subjects be given placebo during the first 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in FVC% (Percent of Predicted FVC value) to week 24Time frame: 24 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Fudan University Affiliated Zhongshan Hospital
Shanghai, China
Xiangya Third Hospital of Central South University
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.